NASDAQ : NYXH
Nyxoah SA — Company profile
Healthcare · Medical Instruments & Supplies · Belgium
Last price 0.8715 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 88.27M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat obstructive sleep apnea. Its lead solution is the Genio system, a hypoglossal neurostimulations therapy for obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Details
| Name | Nyxoah SA |
| Sector | Healthcare |
| Industry | Medical Devices |
| Employees | 153.7 |
| Founded | 2009 |
| Ipo Date | 2021-07-02 |
| Ceo | Liam Kelly |
| Country | Belgium |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Ipo Price | 30.00 |
| Isin | BE0974358906 |
| Cik | 1857190 |
| Sic | 3841 |
Key executives
| Name | Title |
|---|---|
| Liam J. Kelly | Chief Executive Officer |
| Robert Taub MBA | Co-Founder and Chairman |
| Bruno Onkelinx | Chief Technical Officer |
| Loic Moreau | President of International and Interim Chief Financial Officer |
| Jeyakumar Subbaroyan | Chief Science Officer |
| Remi Renard | Head of Investor Relations and Corporate Communication |
| An Moonen | General Counsel |
Contact
| Address | Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium |
| Phone | 32 1 045 90 75 |
| Website | https://www.nyxoah.com |